Targeting neurodegenerative diseases using risuteganib

Video
Conference|ARVO


Dr Glenn J. Jaffe, professor of ophthalmology, Dr Robert Machemer, Distinguished Professor of Ophthalmology, Chief, Division of Retinal Ophthalmology at the Duke University School of Medicine, discusses the key points of his virtual presentation," Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells (Allegro)," including targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised and the need for newer treatment therapies to target different pathways.

See more ARVO content

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
Related Content
A single tear on a person's face. Image credit: ©Chepko Danil – stock.adobe.com

ARVO 2024: Non-invasive testing could use tear film to screen for changes in Huntington Disease

May 7th 2024
Article

The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease

A young girl undergoes an eye exam. Image credit: ©Alexis S/peopleimages.com – stock.adobe.com

ARVO 2024: Children with CVI experience lower vision-specific quality of life, study results indicate

May 6th 2024
Article

Investigators say children with cortical/cerebral visual impairment experience markedly lower vision-specific quality of life

A child has their blood sugar tested using a digital glucometer. Image credit: ©Africa Studio – stock.adobe.com

ARVO 2024: Diabetic retinopathy risk factors in paediatric patients with Type 1 diabetes

May 5th 2024
Article

Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy

A group of children run outside. Image credit: ©JackF – stock.adobe.com

ARVO 2024: CHAMP phase 3 trial shows myopia controlled by low-dose atropine 0.01% over 4-year course

May 5th 2024
Article

This study also investigated the development of myopia rebound when dosing was discontinued

Susana Chung, OD, PhD, talks about her ARVO presentation titled "How similar is reading with central vision loss to reading in normal peripheral vision?"

ARVO 2024: New research indicates the need for a new approach to central vision loss

May 5th 2024
Article

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

An illustration shows the central nervous system with long pink lines to indicate sensory information. Image credit: ©Degimages – stock.adobe.com

ARVO 2024: Murine model of multiple sclerosis demonstrates correlation between visual markers and motor-sensory deficits

May 5th 2024
Article

Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model

© 2024 MJH Life Sciences

All rights reserved.